Catalyst Event
Novartis AG (NVS) · Earnings Release
From KEDI Global Longevity Bio Index (KGLB)
4/28/2026, 12:00:00 AM
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
Korean Translation
2026-04-28에 2026년 1분기 실적 발표 예정됨. 주요 재무 업데이트로 높은 영향력이 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM